Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K14 | Q99558 | 2/20 | 0.50 |
| ▸ | PTGES | O14684 | 7/20 | 0.47 |
| ▸ | JAK2 | O60674 | 2/20 | 0.47 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.47 |
| ▸ | EIF2AK2 | P19525 | 6/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | HTR1B | P28222 | 1/20 | 0.40 |
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
| ▸ | HTR2C | P28335 | 1/20 | 0.40 |
| ▸ | HTR7 | P34969 | 1/20 | 0.40 |
| ▸ | HTR3A | P46098 | 1/20 | 0.40 |
| ▸ | HTR6 | P50406 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10067391 | 0.88 | KDM4E (0.45) | PTGESMAPTKDM4EMEN1ALDH1A1 | |
| SCHEMBL10067256 | 0.88 | MEN1 (0.56) | EIF2AK2MAPTKDM4EMEN1ALDH1A1 | |
| SCHEMBL16629721 | 0.86 | KDM4E (0.43) | MAP3K14PTGESJAK2EIF2AK2MAPT | |
| Apto-253 SCHEMBL10067266 | 0.86 | KDM4E (0.43) | PTGESJAK2EIF2AK2MAPTKDM4E | |
| Apto-253 SCHEMBL29936273 | 0.86 | KDM4E (0.43) | PTGESJAK2EIF2AK2MAPTKDM4E | |
| SCHEMBL10067257 | 0.86 | KDM4E (0.43) | MAPTKDM4EMEN1ALDH1A1LMNA | |
| Apto-253 SCHEMBL29526147 | 0.86 | KDM4E (0.43) | PTGESJAK2EIF2AK2MAPTKDM4E | |
| SCHEMBL10067329 | 0.84 | EIF2AK2 (0.47) | PTGESEIF2AK2MAPTKDM4EMEN1 | |
| SCHEMBL10067288 | 0.81 | GABRA1 (0.47) | MAPTKDM4EMEN1ALDH1A1LMNA | |
| SCHEMBL14707637 | 0.81 | KDM4E (0.42) | PTGESJAK2EIF2AK2MAPTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3650023-A1 | COMPOSITIONS FOR TREATING CANCERS | Aptose Biosciences Inc. (CA) | 2020-05-13 | — | — | EP | disclosed |
| US-20170335400-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCERS | APTOSE BIOSCIENCES INC. (CA) | 2017-11-23 | — | — | US | disclosed |
| US-9567643-B2 | Compositions and methods for treating cancers | APTOSE BIOSCIENCES INC. (CA) | 2017-02-14 | — | — | US | disclosed |
| WO-2015051304-A1 | COMPOSITIONS, BIOMARKERS AND THEIR USE IN TREATMENT OF CANCER | APTOSE BIOSCIENCES INC. (CA) | 2015-04-09 | — | — | WO | disclosed |
| WO-2015051302-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCERS | APTOSE BIOSCIENCES INC. (CA) | 2015-04-09 | — | — | WO | disclosed |
| US-8148392-B2 | 2-indolyl imidazo [4,5-d] phenanthroline derivatives and their use in the treatment of cancer | LORUS THERAPEUTICS INC. (CA) | 2012-04-03 | — | — | US | disclosed |
| US-8148392-B2 | 2-indolyl imidazo [4,5-d] phenanthroline derivatives and their use in the treatment of cancer | LORUS THERAPEUTICS INC. (CA) | 2012-04-03 | — | — | US | disclosed |
| WO-2010102393-A1 | 2-INDOLYL IMIDAZO [4,5-D]PHENANTHROLINE DERIVATIVES AND THEIR USE TO INHIBIT ANGIOGENESIS | LORUS THERAPEUTICS INC. (CA) | 2010-09-16 | — | — | WO | disclosed |
| US-20100168417-A1 | 2-Indolyl Imidazo [4,5-d] Phenanthroline Derivatives and Their Use in the Treatment for Cancer | APTOSE BIOSCIENCES INC. (CA) | 2010-07-01 | — | — | US | disclosed |
| US-20100168417-A1 | 2-Indolyl Imidazo [4,5-d] Phenanthroline Derivatives and Their Use in the Treatment for Cancer | APTOSE BIOSCIENCES INC. (CA) | 2010-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170335400-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCERS | NFXL1, MCL1, CBX2 | MAP3K14 1410/4885PTGES 2781/4885JAK2 219/4885 |
| US-20100168417-A1 | 2-Indolyl Imidazo [4,5-d] Phenanthroline Derivatives and Their Use in the Treatment for Cancer | FLI1, IKZF3, IKZF2 | MAP3K14 2967/4885PTGES 1934/4885JAK2 759/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.